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Abstract
Statins have been shown to induce a phosphoprotein signature that modifies 
MYC (myelocytomatosis viral oncogene) activation and to have anti- 
inflammatory activity that may impact the risk of Non- Hodgkin’s lymphoma 
(NHL). We analyzed the relationship between statins and risk of NHL using 
data from the Women’s Health Initiative (WHI). The study population in-
cluded 161,563 postmenopausal women ages 50–79 years from which 712 
cases of NHL were diagnosed after 10.8 years of follow- up. Information on 
statin use and other risk factors was collected by self- and interviewer- 
administered questionnaires. Multivariable- adjusted HR and 95% CI evaluating 
the relationship between statin use at baseline, as well as in a time- dependent 
manner and risk of NHL, were computed from Cox proportional hazards 
analyses. A separate analysis was performed for individual NHL subtypes: 
diffuse large B- Cell lymphoma (DLBCL) (n = 228), follicular lymphoma 
(n = 169), and small lymphocytic lymphoma (n = 74). All statistical tests 
were two- sided. There was no significant association between use of statins 
at baseline and risk of NHL (HR 0.85, 95% C.I. 0.67–1.08). However, in the 
multivariable- adjusted time- dependent models, statin use was associated with 
a borderline lower risk of NHL (HR 0.81, 95% C.I. 0.66–1.00). Considering 
subtypes of NHL, statin use was associated with a lower risk of DLBCL (HR 
0.62, 95% C.I. 0.42–0.91). This effect was driven by lipophilic statins (HR 
0.62, 95% C.I. 0.40–0.96). In the WHI, statins were associated with a lower 
overall risk of DLBCL, particularly attributable to lipophilic statins. These 
results may have impact on primary or secondary prevention of NHL, par-
ticularly DLBCL.
Cancer Medicine
Open Access
2122 © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
P. Desai et al.Statins and Risk of NHL
Introduction
Statins are the most widely prescribed cholesterol- lowering drugs 
in the United States. According to the latest Centers for Disease 
Control data in the years 2005–2008, the percent of US adults 
taking statins had increased to 25% [1] compared to an esti-
mated 11.7% in 2003–2004 [2]. Statins are a class of drugs 
used for lowering cholesterol and act by competitive inhibition 
of hydroxy methyl glutaryl coenzyme A (HMG CoA), which 
is the rate- limiting enzyme in the mevalonate pathway. Inhibition 
of the mevalonate pathway also leads to lower levels of down-
stream products including farnesyl diphosphate (FPP), gera-
nylgeranyl diphosphate (GGPP), and dolichol [3, 4] which 
may have implications for chemoprevention of cancer.
Mouse models have demonstrated proapoptotic and anti-
tumor activity of statins against lymphoma [5]. Statins have 
also been shown to prevent and reverse MYC- induced lym-
phoma [6]. In addition, the anti- inflammatory effect of statins 
may be an important mechanism of reduction in risk of 
lymphoma as chronic inflammation may be a risk factor [7].
Epidemiological studies of the association of statins and 
risk of lymphoid malignancies have shown mixed results 
with some studies showing lower risk [8–10] while others 
showing increased risk or no association [11, 12]. Statin 
use and its association with solid malignancies has been 
extensively studied in the Womens Health Initiative cohort 
[13–15]. In this report, we analyze the relationship between 
statin use, statin type, potency, and lipophilicity with risk 
of NHL overall and NHL subtypes in a large, multisite 
cohort of postmenopausal women.
Methods
Study population
The study population included 161,808 postmenopausal 
women aged 50 to 79 enrolled in the Women’s Health 
Initiative (WHI) Clinical Trial (CT) and Observational Study 
(OS) from October 1, 1993 to December 31, 1998. Study 
implementation details have been published previously [16–
18]. Follow- up continued from study initiation until planned 
termination in March, 2005, and thereafter for participants 
providing reconsent. The data collection for the current 
analysis was updated through September 2012. Some women 
continue to be followed in the extension study. We excluded 
women from the analysis who had a prior history of lym-
phoma (n = 243) and for whom there was no information 
on statin use (n = 2) for a final analysis cohort of 161,563.
Statin exposure
Statin use was defined as use of any HMG CoA reductase 
inhibitor. Statins were classified as lipophilic (lovastatin, 
simvastatin, fluvastatin, atorvastatin) or hydrophilic 
(pravastatin) and by potency as low potency (fluvastatin 
and lovastatin), medium potency (pravastatin), and high 
potency (simvastatin and atorvastatin) [19, 20].
Information on statin use was collected at baseline in 
the WHI, and thereafter follow- up information on statin 
use was determined at year 3 in the OS participants and 
years 1, 3, 6, and 9 in the CT participants. At baseline 
and at each follow- up visit, participants were asked to 
bring all of their current prescription medications to the 
clinic visit (or first interview at baseline). At those visits, 
interviewers entered each medication name directly from 
the medication containers into the WHI database, which 
assigned drug codes using Medispan software (First 
DataBank, Inc., San Bruno, CA). At the time of the visit, 
women also reported duration of statin use.
NHL
Self- report of NHL was locally verified at each clinic by 
medical record and pathology report review by centrally 
trained WHI physician adjudicators. Central adjudication 
and coding of histology were performed at the Clinical 
Coordinating Center using the Surveillance, Epidemiology, 
and End Results Program (SEER) coding system. Only 
NHL cases confirmed by central adjudication were included 
in the analysis (1091 cases). Information on subtype of 
NHL was available and included 368 cases of diffuse large 
B- Cell lymphoma (DLBCL), 255 cases of follicular lym-
phoma, 96 cases of small lymphocytic lymphoma (SLL), 
and the rest were categorized as other lymphoma type. 
There were two cases where the diagnosis was not adju-
dicated and were not included in the analysis.
Covariates
Information on all covariates was collected at study entry 
including sociodemographic characteristics, clinical history 
as well as factors associated with healthcare utilization 
which might impact both statin utilization and detection 
or diagnosis of NHL.
Statistical analysis
The characteristics of statin users at baseline were com-
pared with those of nonusers by chi- squared tests. 
Annualized rates of NHL (incidence per person- year) were 
calculated according to the use of statins. We performed 
selected subgroup analyses by information on duration 
of statin use (only available at baseline; <1 year, 1–<3 years, 
and ≥3 years), statin type, potency, and lipophilic status. 
Women who reported using two or more statins were 
included in analyses that compared statin use to none, 
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but were excluded from analyses that examined details 
of statin use (by type, potency, or lipophilic status). Hazard 
ratios (HRs) for NHL among statin users versus nonusers, 
and 95% confidence intervals (CIs) were computed from 
Cox proportional hazards analyses. A Cox model that 
included statin use and the interaction of statin use with 
follow- up time and testing for a zero coefficient on the 
interaction term was used to conduct tests for the pro-
portional hazards assumptions.
While only 7.5% of WHI participants used statins at 
baseline, approximately 25% were using statins at the end 
of the trial completion. In order to account for increasing 
statin use during follow- up, we examined the association 
of statin use and NHL using time- dependent analyses. 
To evaluate the effect of change in statin use overtime, 
final models were run by entering statin use as a time- 
dependent exposure and using updated information on 
statin use gathered at each follow- up time point. Cases 
of NHL as well as noncases were censored if they occurred 
more than 3 years after last medication update in the 
OS participants to closely parallel the follow- up experience 
of women in the CT. A set of covariates was selected a 
priori for adjustment of potential confounding based on 
covariates that are associated with risk of NHL or heath-
care utilization. These included age (continuous), history 
of lupus and rheumatoid arthritis at WHI baseline (yes/
no), and current medical care provider (at WHI baseline, 
yes/no). Additionally, all models included strata for age 
group at WHI enrollment, extension study (yes/no), and 
study group/trial participation.
Additional WHI baseline variables were individually 
tested as possible confounders: BMI, race/ethnicity, smok-
ing status, education, percent energy from fats, recreational 
physical activity, waist circumference, aspirin use, history 
of cardiovascular diseases, and postmenopausal hormone 
use. We compared results from models that included all 
of the a priori covariates and each potential confounder 
to models including the a priori covariates only. Covariates 
were considered to be confounders if their inclusion in 
a model resulted in a change in any of the HRs for the 
statin variables by 10% or more. None of the additional 
variables met these criteria; therefore, the results presented 
are those from the models adjusted for the a priori 
covariates.
Separate analyses were conducted for individual subtypes 
of NHL (diffuse large B- cell lymphoma (DLBCL), small 
lymphocytic lymphoma (SLL), marginal zone lymphoma 
(MZL), and follicular lymphoma).
Results
Table 1 shows the baseline characteristics of statin users 
and nonusers. Statin users were more likely to be older, 
have a higher BMI and waist circumference, report having 
a healthcare provider, and to have more than 30% intake 
of energy from fat.
Table 2 shows the distribution of statin use at baseline 
by type, duration, potency, and lipophilicity. Simvastatin 
was the most common statin used with 29.3% of par-
ticipants using it at baseline. The majority of statin users 
took lipophilic statins (69.4%) and 39.3% of users were 
on a statin classified as low potency, 38.2% high potency 
and 22.5% medium potency. Among statin users at base-
line, the percentage of participants using statins for <1 year, 
1–<3 years, and ≥=3 years was 33.1%, 33.9%, and 32.9%, 
respectively.
Table 3 shows the relationship between baseline statin 
use and risk of NHL by overall statin use, statin type, 
potency, and lipophilicity. The annualized rate of NHL 
among statin users and nonusers was 0.06% and 0.05%, 
respectively, with a mean follow- up of 12.57 years for 
statin users and 11.82 years for nonusers. Overall statin 
use at baseline was not associated with risk of NHL (HR 
0.85, 95% C.I. 0.67–1.08). There was no significant asso-
ciation between statin lipophilicity, potency, type or dura-
tion of use, and risk of NHL.
Table 4 shows the association of statin use and risk 
of NHL by overall statin use, statin type, potency, and 
lipophilicity using time- dependent models. In the 
multivariable- adjusted time- dependent model, statin use 
was associated with a borderline significant lower risk of 
NHL compared to nonusers (HR 0.81, 95% C.I. 0.66–1.00) 
and in an analysis by statin lipophilicity, there was a 
suggestion of lower risk of NHL seen with use of lipo-
philic statins (HR 0.83, 95% C.I. 0.66–1.03). For hydro-
philic statins, the HR for NHL was 0.76, 95% C.I. 
0.49–1.22).
Table 5 shows the time- dependent multivariable- adjusted 
relationship between statin use and risk of NHL by his-
tologic subtype. Statin use was associated with a reduced 
risk of DLBCL (HR 0.62, 95% C.I. 0.42–0.91). This effect 
was mostly driven by lipophilic statins (HR 0.62, 95% 
C.I. 0.40–0.96). No association was seen between risk of 
DLBCL and statin potency or individual statin type. There 
was no significant relationship between statins and risk 
of follicular lymphoma (HR 0.96, 95% C.I. 0.64–1.43), 
marginal zone lymphoma (HR 0.76, 95% C.I. 0.39–1.46), 
or SLL (HR 0.98, 95% C.I. 0.72–1.34).
Discussion
We analyzed the association of statins and risk of NHL 
over a long period of follow- up and showed in a time- 
dependent analysis that statin use was associated with a 
borderline lower risk of NHL. Furthermore, we found 
that statin use is specifically associated with a statistically 
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Table 1. Baseline characteristics by statin use.
No Yes
P- valueN % N %
Age group at screening
50–59 51,368 34.35 2189 17.88 <.0001
60–69 66,219 44.27 6370 52.03
70–79 31,976 21.38 3684 30.09
Median age at screening 63 year 66 year <.0001
Race/ethnicity
White 12,3494 82.57 10046 82.06 <.0001
Black 13,499 9.03 1118 9.13
Hispanic 6100 4.08 384 3.14
American Indian 665 0.44 48 0.39
Asian/Pacific Islander 3720 2.49 470 3.84
Unknown 2085 1.39 177 1.45
Education
<HS diploma/GED 7850 5.29 794 6.53 <.0001
HS diploma/GED 25,061 16.88 2563 21.07
>HS diploma/GED 115,517 77.83 8805 72.40
Smoking status
Never 75,545 51.18 5884 48.78 <.0001
Past 61,667 41.77 5442 45.12
Current 10,406 7.05 736 6.10
Alcohol
Non drinker 43,579 29.36 4221 34.70 <.0001
≤1 drink/day 48,774 32.86 4088 33.60
>1 drink/day 56,064 37.77 3856 31.70
Hormone therapy use
Never 65,272 43.68 5612 45.89 <.0001
Past 23,760 15.90 2169 17.74
Current 28,218 40.42 2222 36.37
Body mass index (kg/m2)
<25 53,313 35.96 3021 24.88 <.0001
25–<30 50,858 34.31 4822 39.72
≥30 44,068 29.73 4297 35.40
Median body mass index (kg/
m2)
26.8 28.0 <.0001
Physical activity, met/wk
Inactive 0 METs 22,703 15.94 1759 14.73 <.0001
 [0,3.75) METs 20,789 14.60 1831 15.33
 [3.75, 8.75) METs 29,140 20.46 2626 21.99
 [8.75, 17.5) METS 32,101 22.54 2784 23.31
≥17.5 METS 37,660 26.45 2942 24.64
Waist circumference >88 cm
No 91,023 61.08 6153 50.43 <.0001
Yes 58,000 39/92 6049 49.57
≥30% energy from fat
No 52,486 35.16 5370 43.92 <.0001
Yes 96,800 64.84 6856 56.08
Current healthcare provider
No 9800 6.62 195 1.61 <.0001
Yes 138,286 93.38 11950 98.39
History of lupus
No 146,729 99.50 12,133 99.59 0.1587
Yes 743 0.50 50 0.41
History of rheumatoid arthritis
No arthritis 78,683 54.39 5484 45.99 <.0001
Rheumatoid arthritis 7185 4.97 686 5.75
Other arthritis/don’t know 58,797 40.64 5754 48.26
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significant lower risk of DLBCL. The inverse association 
with statins was restricted to lipophilic statins, but an 
association with other statins cannot be ruled out. It is 
also possible that the results may be due to residual 
confounding.
Table 6 includes an outline of longitudinal studies 
evaluating the relationship between statin use and NHL 
risk. Our findings are supported by the results of three 
other studies demonstrating a reduced risk of NHL among 
statin users [8–10]; however, two other studies reported 
no significant impact of statins [11, 12]. In an analysis 
of the Cancer Prevention Study II Nutrition Cohort 
(CPS- II), Jacobs et al. demonstrated that statin use for 
five or more years was associated with a reduction in 
risk of several cancers including NHL overall (HR = 0.74, 
95% CI 0.62–0.89) as well as DLCL (RR = 0.68, 95% 
CI 0.46–1.00) and marginal zone lymphoma (RR = 0.36, 
95% CI 0.15–0.86) [9]. In a case–control study nested 
in a cohort of 547 UK general practices, comprising of 
7285 cases of hematologic malignancies (including lym-
phoma, myeloma, and leukemia), Vinogradova et al. [10] 
reported that ever use of statins was associated with a 
reduced risk (HR = 0.78, 95% CI 0.71–0.86). Lastly in 
the EPI- LYMPH case–control study comprising 2362 cases 
of incident lymphomas and 2206 controls, ever use of a 
statin was associated with a lower risk of lymphoma (OR 
0.61, 95% C.I. 0.45–0.84) [8]. In contrast, a U.S. case–
control study of 4913 cancer cases, of which 144 were 
NHL cases, did not result in a reduction in risk of lym-
phoma [12] while a Japanese case–control with 221 cases 
showed an increased risk of lymphoma associated with 
statins (OR 2.11, 95% CI 1.20–3.69) [11]. Our analysis 
was only the second cohort study to look at the relation-
ship between statins and lymphoma risk. While in contrast 
to others, our study only included women by design, we 
had a larger cohort size than the Jacobs et al. study, 
however, fewer cases of NHL. In addition, as were others, 
we were able to analyze the relationship of statin subtype 
with NHL risk. Our results, however, were comparable 
to Jacob’s et al. showing a lower risk of DLBCL. We, 
however, did not see a significant reduction in marginal 
zone lymphoma.
Results from a number of preclinical studies suggest 
that our current observation is biologically plausible. Statins 
have been previously shown to have chemopreventive 
effects for a large number of cancer types based on their 
downstream molecular effects [21, 22]. Reports examining 
the in vitro impact of statins have shown that statins 
possess antiproliferative, apoptotic, and anti- invasive prop-
erties resulting from their ability to target multiple signaling 
pathways within malignant cells [21–29]. Statins have been 
shown to reduce the farnesylation of Ras needed for its 
attachment to the cellular membrane [23], and Ras is 
involved in many intracellular pathways and has been 
shown to increase gene transcription and proliferation 
via MEK and PI3K/Akt signaling [21].
Statins have also been shown to inhibit the production 
of FPP and GPPP, two key downstream products involved 
in posttranslational modification of many proteins includ-
ing geranylgeranylation of Rho proteins (Rho GTPases) 
[30]. In turn, these gene products regulate Rho kinases, 
which are involved in various cellular functions including 
gene expression, actin cytoskeleton migration, adhesion, 
and contractility of cells [31]. Thus, by inhibiting the 
production of GGPP, statins may have antiproliferative 
and anti- invasive properties. Statins have also been impli-
cated in G1- S arrest [32]. Lastly, studies using transgenic 
mouse models have demonstrated that statins possess 
proapoptotic and antitumor activity against lymphoma 
[5]. Data from Ajith et al. indicate that statin- induced 
apoptosis depends on their ability to inhibit lipid per-
oxidation and depleted key geranylgeranylated proteins. 
Shachaf et al. have described a transgenic mouse model 
in which atorvastatin reverses the development of MYC- 
induced lymphomas in a dose- dependent fashion [6]. In 
this latter model, atorvastatin was found to delay the 
onset of lymphoma, helping to purge neoplastic cells from 
the bone marrow. These effects were negated if Ras was 
Table 2. Distribution of statins by type, duration, and other statin 
characteristics.
No Yes
N % N %
Statin type
No statin use 14,9563 100.00
Atorvastatin calcium 961 7.85
Fluvastatin sodium 1484 12.12
Lovastatin 3204 26.17
Pravastatin sodium 2686 21.94
Simvastatin 3589 29.31
Two or more statins 319 2.61
Statin potency
No statin use 149,563 100.00
Low (Lovastatin, 
Fluvastatin)
4688 39.32
Medium (Pravastatin) 2686 22.53
High (Simvastatin, 
Atorvastatin)
4550 38.16
Lipophilicity
No statin use 149,563 100.00
Lipophilic statins 8277 69.41
Hydrophilic statins 
(pravastatin)
3647 30.59
Statin use in years
No statin use 149,563 100.00
<1 4054 33.11
1–<3 4151 33.91
≥3 4038 32.98
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Table 4. Non- Hodgkin’s lymphoma (NHL) HRs by time- dependent statin use.
NHL 
cases
Age adjusted Multivariable adjusted
Hazard ratio Lower CL Upper CL P- value Hazard ratio Lower CL Upper CL P- value
Statin use
No 660 1.00 1.00
Yes 53 0.82 0.68 1.00 0.05 0.81 0.66 1.00 0.04
Statin type
No statin use 660 1.00 1.00
Atorvastatin calcium 2 0.81 0.60 1.09 0.15 0.84 0.62 1.13 0.24
Fluvastatin sodium 6 0.66 0.31 1.38 0.27 0.58 0.26 1.31 0.19
Lovastatin 17 1.09 0.66 1.79 0.74 1.00 0.59 1.70 0.99
Pravastatin sodium 11 0.79 0.49 1.29 0.35 0.79 0.48 1.30 0.36
Simvastatin 15 0.88 0.62 1.24 0.46 0.85 0.59 1.22 0.37
Lipophilicity
No statin use 660 1.00 1.00
Lipophilic statin 40 0.84 0.68 1.04 0.11 0.83 0.66 1.03 0.09
Hydrophilic statin 11 0.77 0.50 1.21 0.26 0.76 0.49 1.22 0.28
Statin potency
No statin use 660 1.00 1.00
Low (Lovastatin, 
  Fluvastatin)
23 0.89 0.58 1.35 0.57 0.81 0.52 1.26 0.34
Medium (Pravastatin) 11 0.78 0.48 1.26 0.30 0.77 0.47 1.27 0.31
High (Simvastatin, 
  Atorvastatin)
17 0.83 0.65 1.04 0.11 0.83 0.65 1.06 0.13
Stratified by trial, WHI extension study, and age group.
Base model was adjusted by age.
Multivariable model adjusted for age, current medical care provider, history of lupus, history of rheumatoid arthritis.
Table 5. Diffuse large B- Cell lymphoma (DLBCL) HRs by time- dependent statin use.
DLBCL 
cases
Age adjusted Multivariable adjusted
Hazard ratio Lower CL Upper CL P- value Hazard ratio Lower CL Upper CL P- value
Statin use
No 215 1.00 0.02 1.00 0.02
Yes 13 0.65 0.45 0.94 0.62 0.42 0.91
Statin type
No statin use 215 1.00 1.00
Atorvastatin 1 0.69 0.40 1.19 0.18 0.69 0.39 1.23 0.21
Fluvastatin 1 0.26 0.04 1.89 0.18 0.000 0.000 0.97
Lovastatin 2 0.59 0.19 1.83 0.36 0.63 0.20 1.98 0.43
Pravastatin 5 0.68 0.28 1.65 0.40 0.58 0.22 1.58 0.29
Simvastatin 4 0.83 0.45 1.52 0.54 0.81 0.43 1.54 0.53
Lipophilicity
No statin use 215 1.00 1.00
Lipophilic 8 0.65 0.43 0.97 0.04 0.62 0.40 0.96 0.03
Hydrophilic 5 0.79 0.37 1.67 0.53 0.72 0.32 1.63 0.43
Statin potency
No statin use 215 1.00 1.00
Low (Lovastatin, 
Fluvastatin)
3 0.44 0.16 1.18 0.10 0.35 0.11 1.10 0.07
Medium 
(Pravastatin)
5 0.67 0.27 1.62 0.37 0.57 0.21 1.54 0.27
High (Simvastatin, 
Atorvastatin)
5 0.74 0.48 1.12 0.15 0.73 0.47 1.14 0.16
Stratified by trial, WHI extension study, and age group.
Base model was adjusted by age.
Multivariable model adjusted for age, current medical care provider, history of lupus, history of rheumatoid arthritis.
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constitutively activated. The specific pathway by which 
statins exert this effect is by inactivating MYC following 
disruption of upstream Ras/ERK ½ pathways.
Another mechanism by which statins may impact risk 
of lymphoma is through inhibition of histone deacetylases 
(HDACs). It has been recently shown that the carboxylic 
moiety of lovastatin can bind and chelate the catalytic 
site of HDAC2, leading to increased p21 expression and 
inhibition of tumor cell growth [33]. HDAC inhibition 
has been targeted in a number of hematologic malignan-
cies including lymphoma [34]. Lastly, the anti- 
inflammatory effect of statins may be an important 
mechanism of reduction in risk of lymphoma as chronic 
inflammation is a possible risk factor for lymphoma [7].
Our observation that statins differentially impact lym-
phoma risk based on their biologic properties is also 
consistent with the exiting medical literature [21, 35]. 
Statins are classified according to their solubility in octanol 
(lipophilicity) and water (hydrophilicity) [16]. Lipophilic 
statins (lovastatin, simvastatin fluvastatin, and atorvastatin) 
penetrate the plasma member while hydrophilic statins 
(pravastatin) do not. A number of in vitro studies have 
shown that lipophilic statins possess the most robust anti-
cancer properties, consistent with the observations reported 
above.
The strengths of our analysis include the prospective 
design, the large diverse population with detailed demo-
graphic characterization, adjudicated cancer diagnosis by 
central review, serial update of statin use, and long follow-
 up period. The comprehensive data collection in the WHI 
also allows for a detailed adjustment for confounding 
variables. Limitations include the observational nature and 
the relatively low prevalence of statin use at baseline among 
WHI subjects. Despite these limitations, we were able to 
capture updated information on statin use using a time- 
dependent analysis. Another limitation is the lack of data 
documenting medication compliance and HIV status, 
another risk factor for NHL. It is currently thought that 
the prevalence of HIV in the WHI cohort of 
postmenopausal women is low. We also did not have 
dose information on statins and were not able to analyze 
relationship of dosing or duration of use in the time- 
dependent analysis. Our results suggesting a relationship 
between lipophilic statins and NHL may be particularly 
important for high- risk populations such as those with 
autoimmune conditions. Our findings showing a specific 
impact on DLBCL have implications for future studies 
of the impact of statins on risk of recurrent disease.
Conclusion
Statin use may be associated with a lower risk of NHL 
in women particularly DLBCL. These results should be 
evaluated in other large datasets, particularly meta- analyses 
of trial data, with a particular emphasis on specific type 
of NHL.
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